Use of Perindopril Arginine/Indapamide/Amlodipine in the Management of Hypertension in Two Sub-Saharan African Island Countries of Madagascar and Mauritius.

Autor: Mbanya A; Health of Population in Transition Research Group, University of Yaoundé I, Yaoundé, Cameroon., Ackbarkhan A; Cardiology Clinic, Port Louis, Mauritius., Mittoo MY; General Practice Clinic, Curepipe, Mauritius., Ramamonjisoa HA; Department of Diabetology, AMADIA Diabetology Clinic, Antananarivo, Madagascar., Ramilitiana B; Department of Internal Medicine, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar., Ranivoharisoa EM; Department of Nephrology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar., Ratsimbazafy SJN; Department of Internal Medicine, University Hospital Soavinandriana, Antananarivo, Madagascar., Mbanya JC; Health of Population in Transition Research Group, University of Yaoundé I, Yaoundé, Cameroon. jcmbanya3@gmail.com.; Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. jcmbanya3@gmail.com.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2850-2861. Date of Electronic Publication: 2022 Apr 18.
DOI: 10.1007/s12325-022-02134-0
Abstrakt: Introduction: Most patients with hypertension in sub-Saharan Africa require two or more drugs to control their blood pressure. Triple fixed-dose combination therapy of perindopril arginine/indapamide/amlodipine is more effective in lowering blood pressure, offers better target organ protection and has increased adherence compared to monotherapy and free combination therapy, and is safe to use. This observational study evaluates the effectiveness of perindopril arginine/indapamide/amlodipine in controlling blood pressure at least 1 month after treatment initiation and assesses patient- and physician- reported drug tolerance over a 3-month period in Madagascar and Mauritius.
Methods: A total of 198 patients with hypertension in ambulatory care who had been on fixed-dose combination of perindopril arginine, indapamide, and amlodipine for at least 4 weeks were included. The main outcome measures were changes in systolic and diastolic blood pressure, attainment of blood pressure control under 140/90 mmHg and 130/80 mmHg, self-reported drug tolerance by the patient, and perceived drug tolerance by the treating physician. Data was collected at 1 month and 3 months.
Results: Mean systolic blood pressure was significantly lower at the 1-month (- 3.4 mmHg, p = 0.002) and 3-month (- 8.5 mmHg, p < 0.0001) visits. Diastolic blood pressure also decreased significantly (- 2.4 mmHg at 1-month, p = 0.017 and - 5.4 mmHg at the 3-month visits, p < 0.0001). At 3 months, 80.4% of the patients attained blood pressure targets less than 140/90 mmHg and 42.7% attained targets less than 130/80 mmHg on the basis of their baseline blood pressure. Excellent drug tolerance was reported by more than 90% of patients and physicians at the 1-month visit and by more than 95% at the 3-month visit.
Conclusion: Triple fixed-dose therapy of perindopril arginine/indapamide/amlodipine continues to show additional blood pressure-lowering capacity even months after initiating the treatment in patients with hypertension in Madagascar and Mauritius. It is also well tolerated by patients with hypertension and assessed as safe to use by physicians.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: